Welcome to our dedicated page for Merck & Co SEC filings (Ticker: MRK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Merck & Co., Inc. filings document the regulatory record of a New Jersey pharmaceutical issuer with common stock and multiple debt securities registered on the New York Stock Exchange. The company's disclosures cover operating and financial results, clinical and regulatory matters, material agreements, governance matters and capital-structure changes.
Merck's SEC record includes Form 8-K material-event reports, definitive proxy materials and debt-financing disclosures. Recent filings describe underwritten public offerings of notes, registered securities, shareholder voting matters, board and executive-governance information, and other events tied to the company's pharmaceutical, vaccine and animal health businesses.
Merck & Co., Inc. Executive VP & President, MRL, Dean Y. Li reported new equity awards. The filing shows a grant of 58,207 stock options with a $113.15 exercise price and a separate grant of 19,885 restricted stock units, each tied to one share of Merck common stock.
The options vest and become exercisable in three equal installments on 5/5/2027, 5/5/2028, and 5/5/2029, and expire on 5/4/2036. The restricted stock units vest and are delivered as shares on the same three annual dates. Following these transactions, Li directly holds 94,431.0500 shares of Merck common stock.
Merck & Co., Inc. executive Betty D. Larson, EVP and Chief HR Officer, reported equity awards and updated her holdings. She now directly holds 13,774 shares of Merck common stock.
On 5/5/2026, she received a grant of 23,283 stock options with an exercise price of $113.15 per share, expiring on 5/4/2036. These options vest in three equal installments on 5/5/2027, 5/5/2028, and 5/5/2029.
She was also granted 7,954 restricted stock units, each representing one share of common stock. These RSUs vest and are distributed in three equal installments on 5/5/2027, 5/5/2028, and 5/5/2029.
Merck & Co., Inc. executive Richard R. DeLuca, EVP & President of Merck Animal Health, reported compensation-related equity grants rather than open-market trades. He received 34,924 stock options with an exercise price of $113.15 per share, which vest in three equal installments on 5/5/2027, 5/5/2028, and 5/5/2029, and expire on 5/4/2036.
DeLuca also received 11,931 restricted stock units, each representing one share of Merck common stock, vesting and settling in three equal installments on 5/5/2027, 5/5/2028, and 5/5/2029. Following these grants, he holds 161,537.0700 common shares directly and 1,320.9907 shares indirectly through a 401(k) plan.
Merck & Co., Inc. Chairman, CEO & President Robert M. Davis reported new equity awards and updated his shareholdings. He now holds 450,350.757 shares of common stock directly. On May 5, 2026, he was granted 139,697 stock options with an exercise price of $113.15 per share, vesting in three equal installments on May 5, 2027, 2028 and 2029. He also received 47,724 restricted stock units, each representing a right to one Merck common share, vesting and settling in three equal installments on May 5, 2027, 2028 and 2029.
Merck & Co., Inc. reported that EVP, Specialty, Pharma, & ID Brian Foard received new equity awards. On May 5, 2026, he was granted a stock option covering 31,044 shares of common stock with an exercise price of $113.15 per share, vesting in three equal annual installments on May 5 of 2027, 2028, and 2029.
He was also granted restricted stock units for 35,351 shares and an additional 10,605 shares. Each restricted stock unit represents a contingent right to receive one share of Merck common stock and vests, with shares distributed, in three equal installments on May 5, 2027, May 5, 2028, and May 5, 2029. These are compensation grants, not open-market purchases or sales.
Merck & Co., Inc. executive David R. Maraldo reported new equity awards and updated holdings. As EVP & Pres. MMD, he received a grant of stock options for 21,731 shares of common stock at an exercise price of $113.15 per share, vesting in three equal installments on 5/5/2027, 5/5/2028, and 5/5/2029. He also received 7,424 restricted stock units, each representing a contingent right to one Merck common share, vesting and settling in three equal installments on those same dates. Following these transactions, he reports direct ownership of 18,212.434 shares of common stock and indirect ownership of 8,359.14 shares through a 401(k) plan.
Oosthuizen Johannes Jacobus reported acquisition or exercise transactions in this Form 4 filing.
Merck & Co., Inc. executive vice president for Oncology & International, Johannes Jacobus Oosthuizen, reported new equity awards. He received a grant of 31,044 stock options, each allowing him to buy Merck common stock at $113.15 per share, expiring in 2036 and vesting in three equal installments on 5/5/2027, 5/5/2028, and 5/5/2029. He was also granted 10,605 restricted stock units, each representing a right to receive one Merck share, vesting and settling in stock in three equal installments on the same dates. Following these awards, he directly holds 21,895.389 shares of Merck common stock.
Merck & Co., Inc. senior vice president of finance and global controller Dalton E. Smart III received new equity awards. He was granted stock options for 5,045 shares of common stock at an exercise price of $113.15 per share and 2,298 restricted stock units, both vesting in three equal annual installments beginning 5/5/2027. Each restricted stock unit represents a contingent right to receive one Merck common share. After these awards, he directly holds 9,388.315 shares of Merck common stock.
Merck & Co., Inc. executive vice president Chirfi Guindo reported new equity awards and updated share holdings. He received a grant of 19,402 stock options with an exercise price of $113.15 per share, vesting in three equal installments on 5/5/2027, 5/5/2028, and 5/5/2029.
He also received 6,628 restricted stock units, each representing one share of common stock, scheduled to vest and be distributed in three equal installments on the same dates. Following these awards, he holds 61,613.127 shares of common stock directly and 57.1377 shares indirectly through a 401(k) plan. These are compensation-related grants rather than open-market purchases or sales.
Merck & Co., Inc. senior vice president of finance and global controller Dalton E. Smart III reported routine equity compensation activity involving restricted stock units. On May 2, 2026, restricted stock units covering 383 shares of common stock were exercised and converted into common shares.
To cover tax obligations, 132 shares of common stock were disposed of in a tax-withholding transaction at $112.16 per share, a non‑market event. After these transactions, Smart directly held 9,388.315 shares of Merck common stock. The restricted stock units, each representing a contingent right to one Merck share, vest and are distributed in three equal installments on May 2 of 2024, 2025, and 2026.